Biotech Values

[biomaven0]

>MDV3100

We still haven't seen any safety data. So that makes me a bit cautious. If it's clean, then I think the stock still has quite a ways to go, although of course this is already a partnered asset. There are substantial milestones in their agreement, and if you back those out the market cap isn't excessive at all if the drug becomes the SOC in prostate.

Peter